Atea Pharmaceuticals, Inc. AVIR 深 滬
已收盤 05-08 16:00:00 美东时间
5.43
-0.110
-1.99%
華盛通- 最 高5.57
- 今 開5.51
- 成交量 23.98万股
- 最 低 5.42
- 昨 收 5.54
- 總市值 4.35亿
- 52周最高 6.45
- 市盈率 靜 --
- 換手率 0.30%
- 52周最低 2.71
- 委 比 77.74%
- 總股本 8002.71万
- 歷史最高 94.174
- 量 比 0.97
- 振 幅 2.71%
- 歷史最低 2.455
- 每 手 1
- 風險率 0.98%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Atea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026
Atea Pharmaceuticals will host a live conference call and webcast on May 12, 2026, at 4:30 p.m. ET to discuss Q1 2026 financial results and provide a business update. Participants can join via phone using conference ID 13759581 or access the webcast at ir.ateapharma.com. The company focuses on developing oral antiviral therapies for serious viral diseases, with a pipeline targeting ssRNA viruses. An archived webcast will be available on Atea’s we...
05-05 11:00
Top 2 Health Care Stocks That May Fall Off A Cliff This Month
Momentum warning for health care sector stocks: RSI indicator shows overbought assets. Arcellx (ACLX) and Atea Pharma (AVIR) among top-ranked.
03-18 20:59
美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价
今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元
03-10 15:05
Atea Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS results.
Atea Pharmaceuticals shares are trading lower after the company reported worse-...
03-06 22:19
Atea Pharmaceuticals Q4 EPS $(0.57) Misses $(0.53) Estimate
Atea Pharmaceuticals (NASDAQ:AVIR) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 42.5 percent decrease over losses of $(0.40) per share
03-06 05:09
Earnings Scheduled For March 5, 2026
Companies Reporting Before The Bell • Palladyne AI (NASDAQ:PDYN) is projected t...
03-05 19:11
Atea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026
Atea Pharmaceuticals announced strong *in vitro* results for AT-587 and AT-2490, potent oral nucleotide analogs targeting Hepatitis E Virus (HEV). Both compounds demonstrated 30-150-fold higher potency than current treatments and showed activity against other viruses without toxicity. Atea plans to begin Phase 1 trials mid-2026, addressing a critical unmet need for HEV patients, especially immunocompromised individuals facing rapid disease progre...
02-24 12:00
Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Atea Pharmaceuticals announced that its CEO, Jean-Pierre Sommadossi, PhD, and other management team members will present at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026. The presentation will be live webcast and available on the company's website for 90 days. Atea, a clinical-stage biopharmaceutical company, focuses on developing oral antiviral therapies for serious viral diseases, leveraging its nucleos(t)ide prodrug pla...
01-06 12:00
Atea Pharmaceuticals Completes Enrollment Of Over 880 Treatment-naïve Patients In C-BEYOND Phase 3 Trial Of Fixed-dose Combination Bemnifosbuvir And Ruzasvir Compared To Sofosbuvir And Velpatasvir Regime For Hepatitis C Virus; Results Are Expected Mid-year 2026
In addition to C-BEYOND, Atea continues to advance enrollment of treatment-naïve patients in C-FORWARD, a Phase 3 trial evaluating this same FDC regimen in 880 patients at approximately 120 clinical trial sites in up to
2025-12-22 20:05
